866-997-4948(US-Canada Toll Free)

Malignant Mesothelioma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 169 Pages


Global Markets Direct’s, \'Malignant Mesothelioma - Pipeline Review, H1 2013\', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Malignant Mesothelioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma. 

Malignant Mesothelioma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Malignant Mesothelioma.
  • A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Malignant Mesothelioma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Malignant Mesothelioma Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Malignant Mesothelioma 12
Malignant Mesothelioma Therapeutics under Development by Companies 14
Malignant Mesothelioma Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Malignant Mesothelioma Therapeutics - Products under Development by Companies 23
Malignant Mesothelioma Therapeutics - Products under Investigation by Universities/Institutes 25
Companies Involved in Malignant Mesothelioma Therapeutics Development 27
Biogen Idec Inc. 27
AstraZeneca PLC 28
Viralytics Ltd. 29
GlaxoSmithKline plc 30
Merck & Co., Inc. 31
Oxford BioMedica plc 32
Plexxikon Inc. 33
Pfizer Inc. 34
Aduro BioTech 35
Bayer AG 36
Aeolus Pharmaceuticals, Inc. 37
AEterna Zentaris Inc. 38
Bionomics Limited 39
University of Pennsylvania 40
Morphotek, Inc. 41
CanBas Co., Ltd. 42
MolMed S.p.A. 43
Y\'s Therapeutics Co., Ltd. 44
Oncolys BioPharma Inc. 45
Genelux Corporation 46
Polaris Group 47
Malignant Mesothelioma - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
sorafenib tosylate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
sorafenib tosylate - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
cediranib maleate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
TroVax - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
AEOL-10150 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NGR-hTNF - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
OBP-801 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CVA-21 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
BG-00001 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
BNC-105 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
amatuximab - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
bortezomib + [cisplatin] - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
imatinib mesylate + [cisplatin] + [pemetrexed disodium] - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
CBP-501 + [cisplatin] + [pemetrexed disodium] - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 86
bevacizumab + [cisplatin] + [gemcitabine hydrochloride] - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
adenoviral mediated interferon beta - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
PLX-3397 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
ADI-PEG 20 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
vorinostat - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
NGR-hTNF + [gemcitabine hydrochloride] - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
NGR-hTNF + [vinorelbine tartrate] - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
GL-ONC-1 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
PF-03446962 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
amatuximab + [cisplatin] + [pemetrexed disodium] - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
GSK-2256098 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
icelecoxib + [decitabine] + [depsipeptide] - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 111
rilotumumab + [cisplatin] + [pemetrexed disodium] - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
CRS-207 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
romidepsin + alvocidib - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
CP-870,893 + [cisplatin] + [pemetrexed disodium] - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
GC-1008 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
BNC-105-P - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Lung Tumor Associated Antigen + [cyclophosphamide] + DetoxPC - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
interferon alfa-2b - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
bortezomib + [oxaliplatin] - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
cetuximab + [carboplatin] + [cisplatin] + [pemetrexed] - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Autologous Tumor Cell Vaccine + [celecoxib] + [Iscomatrix] - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
MV-NIS Vaccine - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
pemetrexed disodium + [cisplatin] - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
Autologous Mesothelin Redirected T Cells - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
BAY-94-9343 - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Dendritic Cell-Based Immunotherapy + [cyclophosphamide] - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
SS1P + [cisplatin] + [pemetrexed disodium] - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
FPI-01 - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
CRS-207 + Cisplatin + Pemetrexed - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
BERTA - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Malignant Mesothelioma Therapeutics - Drug Profile Updates 137
Malignant Mesothelioma Therapeutics - Discontinued Products 157
Malignant Mesothelioma Therapeutics - Dormant Products 158
Malignant Mesothelioma - Product Development Milestones 161
Featured News & Press Releases 161
Nov 12, 2012: Morphotek\'s Amatuximab Receives FDA Orphan Drug Designation For Treatment Of Malignant Pleural Mesothelioma 161
Nov 09, 2012: Verastem Reports Data On Focal Adhesion Kinase Program At 2012 EORTC Symposium On Molecular Targets And Cancer Therapeutics 161
Nov 08, 2012: GSK\'s Mesothelioma Drug Slows Disease Progression In Patients With Inactive NF2 Gene, Study Finds 162
Oct 02, 2012: Aduro Biotech Announces Enrollment Of First Patient In Mesothelioma Phase Ib Trial 163
Sep 07, 2012: Verastem To Present Data On Focal Adhesion Kinase Program At 11th International Conference Of International Mesothelioma Interest Group 164
Aug 24, 2012: US Court Of Appeals Upholds Validity Of Lilly\'s Alimta Compound Patent 164
Jul 18, 2012: Bayer HealthCare Receives Orphan Drug Designation For Anti-Cancer Agent In US For Treatment Of Mesothelioma 165
Jun 18, 2012: MolMed Receives New European Patent For Anticancer Drug NGR-hTNF 165
Jun 04, 2012: CanBas\'s CBP501 Meets Primary Endpoint In Phase II Study Of Malignant Pleural Mesothelioma 166
Jun 04, 2012: MolMed Presents Long-Term Follow Up Data From Phase II Mesothelioma Trial Of NGR-hTNF At ASCO 167

Appendix 168
Methodology 168
Coverage 168
Secondary Research 168
Primary Research 168
Expert Panel Validation 168
Contact Us 169
Disclaimer 169

List of Table


Number of Products Under Development for Malignant Mesothelioma, H1 2013 12
Products under Development for Malignant Mesothelioma - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Comparative Analysis by Late Stage Development, H1 2013 19
Comparative Analysis by Mid Clinical Stage Development, H1 2013 20
Comparative Analysis by Early Clinical Stage Development, H1 2013 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Development by Companies, H1 2013 (Contd..1) 24
Products under Investigation by Universities/Institutes, H1 2013 25
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 26
Biogen Idec Inc., H1 2013 27
AstraZeneca PLC, H1 2013 28
Viralytics Ltd., H1 2013 29
GlaxoSmithKline plc, H1 2013 30
Merck & Co., Inc., H1 2013 31
Oxford BioMedica plc, H1 2013 32
Plexxikon Inc., H1 2013 33
Pfizer Inc., H1 2013 34
Aduro BioTech, H1 2013 35
Bayer AG, H1 2013 36
Aeolus Pharmaceuticals, Inc., H1 2013 37
AEterna Zentaris Inc., H1 2013 38
Bionomics Limited, H1 2013 39
University of Pennsylvania, H1 2013 40
Morphotek, Inc., H1 2013 41
CanBas Co., Ltd., H1 2013 42
MolMed S.p.A., H1 2013 43
Y\'s Therapeutics Co., Ltd., H1 2013 44
Oncolys BioPharma Inc., H1 2013 45
Genelux Corporation, H1 2013 46
Polaris Group, H1 2013 47
Assessment by Monotherapy Products, H1 2013 48
Assessment by Combination Products, H1 2013 49
Assessment by Stage and Route of Administration, H1 2013 51
Assessment by Stage and Molecule Type, H1 2013 53
Malignant Mesothelioma Therapeutics - Drug Profile Updates 137
Malignant Mesothelioma Therapeutics - Discontinued Products 157
Malignant Mesothelioma Therapeutics - Dormant Products 158
Malignant Mesothelioma Therapeutics - Dormant Products (Contd..1) 159
Malignant Mesothelioma Therapeutics - Dormant Products (Contd..2) 160

List of Chart


Number of Products under Development for Malignant Mesothelioma, H1 2013 12
Products under Development for Malignant Mesothelioma - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 19
Mid Clinical Stage Products, H1 2013 20
Early Clinical Stage Products, H1 2013 21
Discovery and Pre-Clinical Stage Products, H1 2013 22
Assessment by Monotherapy Products, H1 2013 48
Assessment by Combination Products, H1 2013 49
Assessment by Route of Administration, H1 2013 50
Assessment by Stage and Route of Administration, H1 2013 51
Assessment by Molecule Type, H1 2013 52
Assessment by Stage and Molecule Type, H1 2013 53

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *